Publications 1997 - 2002

Herpes simplex virus type 1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19.

Heister T, Heid I, Ackermann M, Fraefel C.
J Virol. 2002 Jul;76(14):7163-73

Quantification of feline herpesvirus 1 DNA in ocular fluid samples of clinically diseased cats by real-time TaqMan PCR.

Vögtlin A, Fraefel C, Albini S, Leutenegger CM, Schraner E, Spiess B, Lutz H, Ackermann M.
J Clin Microbiol. 2002 Feb;40(2):519-23

Herpes simplex virus type 1 amplicon vector-mediated gene transfer to muscle.

Wang Y, Mukherjee S, Fraefel C, Breakefield XO, Allen PD.
Hum Gene Ther. 2002 Jan 20;13(2):261-73

Herpes simplex virus/adeno-associated virus hybrid vectors for gene transfer to neurons.

Costantini L.C., C. Fraefel, X.O. Breakefield and O. Isacson
Preparation and use. Methods Mol. Med. 69:461-79 (2002)

HSV-1 amplicon vectors.

Wang S., C. Fraefel and X.O. Breakefield
Methods Enzymol. 346:593-603 (2002)

Transduction of Vero cells and bovine monocytes with a herpes simplex virus-1 based amplicon carrying the gene for the bovine herpesvirus-1 Circ protein.

Schwyzer M., C. Fischer-Bracher, C. Fraefel, T. Bachi, R. Nunez, M. Engels and M. Ackermann
Vet. Microbiol. 86:165-174 (2002). Proceeding

HSV-1-based amplicon particles are able to transduce cells of feline origin with genes encoding biologically functional feline IL-10 or IL-6.

Vogtlin A., C. Fraefel, R. Kocherhans, C.M. Leutenegger, K. Frei, A. Fontana and M. Ackermann
Vet. Microbiol. 86:103-113 (2002). Proceeding

Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome.

Saeki Y, Fraefel C, Ichikawa T, Breakefield XO, Chiocca EA.
Mol Ther. 2001 Apr;3(4):591-601

Flow cytometric assessment of transduction efficiency and cytotoxicity of herpes simplex virus type 1-based amplicon vectors.

Nunez R, Ackermann M, Saeki Y, Chiocca A, Fraefel C.
Cytometry. 2001 Jun 1;44(2):93-9

Viren-Werkzeuge der Gentherapeuten.

Müller L., T. Heister and C. Fraefel
BioWorld 4:14-16 (2001). Review

HSV-1 infected cell proteins influence tetracycline-regulated transgene expression.

Herrlinger U, Pechan PA, Jacobs AH, Woiciechowski C, Rainov NG, Fraefel C, Paulus W, Reeves SA.
J Gene Med. 2000 Sep-Oct;2(5):379-89

Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma.

Herrlinger U, Jacobs A, Quinones A, Woiciechowsky C, Sena-Esteves M, Rainov NG, Fraefel C, Breakefield XO.
Hum Gene Ther. 2000 Jul 1;11(10):1429-38

HSV-1 amplicon vectors are a highly efficient gene delivery system for skeletal muscle myoblasts and myotubes.

Wang Y, Fraefel C, Protasi F, Moore RA, Fessenden JD, Pessah IN, DiFrancesco A, Breakefield X, Allen PD.
Am J Physiol Cell Physiol. 2000 Mar;278(3):C619-26

Recent developments on herpes simplex virus type 1-based amplicon vector systems.

Fraefel C., D. Jacoby and X.O. Breakefield
Adv. Virus Res. 55:425-451 (2000)

HSV-1 amplicon vectors-simplicity and versatility.

Sena-Esteves M., Y. Saeki, C. Fraefel and X.O. Breakefield
Mol. Ther. 2:9-15 (2000)

HSV-1 amplicon and HSV/AAV-based hybrid amplicon vectors for gene transfer experiments in cells in culture and in vivo.

Saeki Y. and C. Fraefel
In: Cid-Arregui A. and A. Garcia-Carranca (eds.), Viral vectors: Basic science and gene therapy. Eaton Publishing, Natick, MA; 211-233 (2000)

Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors.

Costantini LC, Jacoby DR, Wang S, Fraefel C, Breakefield XO, Isacson O.
Hum Gene Ther. 1999 Oct 10;10(15):2481-94. Erratum in: Hum Gene Ther 2000 Apr 10;11(6):981

BAC-VAC, a novel generation of (DNA) vaccines: A bacterial artificial chromosome (BAC) containing a replication-competent, packaging-defective virus genome induces protective immunity against herpes simplex virus 1.

Suter M, Lew AM, Grob P, Adema GJ, Ackermann M, Shortman K, Fraefel C.
Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12697-702

Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment.

Persichetti F, Trettel F, Huang CC, Fraefel C, Timmers HT, Gusella JF, MacDonald ME.
Neurobiol Dis. 1999 Oct;6(5):364-75

HSV-1-Based Vectors for Gene Therapy of Neurological Diseases and Brain Tumors: Part II.

Jacobs A., X.O. Breakefield and C. Fraefel
Vector Systems and Applications. Neoplasia 1: 402-416 (1999)

HSV-1-Based Vectors for Gene Therapy of Neurological Diseases and Brain Tumors: Part I. HSV-1 Structure, Replication and Pathogenesis.

Jacobs A., X.O. Breakefield and C. Fraefel
Neoplasia 1: 387-401 (1999)

Gene delivery using helper virus-free HSV-1 amplicon vectors. In: Crawley J., et al. (eds.), Current Protocols in Neurosciences.

Fraefel C
John Wiley & Sons, Inc., New York; 4.14.1.-4.14.16 (1999)

Helper virus-free herpesvirus vector packaging system.

Fraefel C., A.I. Geller and F. Lim
(1998/1999). United States Patents 5,851,826 and 5,998,208

Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors.

Saeki Y, Ichikawa T, Saeki A, Chiocca EA, Tobler K, Ackermann M, Breakefield XO, Fraefel C.
Hum Gene Ther. 1998 Dec 10;9(18):2787-94

A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma.

Rainov N.G., M. Sena-Esteves, C. Fraefel, K.U. Dobberstein, E.A. Chiocca and X.O. Breakefield
Adv. Exp. Med. Biol. 451:393-403 (1998)

HSV-1 amplicon. In: Chiocca E.A. and X.O. Breakefield (eds.), Gene therapy for neurological disorders and brain tumors.

Fraefel C., X.O. Breakefield and D. Jacoby
Humana Press, Totowa; 63-82 (1998)

Gene therapy for ischemic stroke.

Pechan P., M. Fujii, C. Fraefel, A. Jacobs and M.A. Moskowitz
In: Chiocca E.A. and X.O. Breakefield (eds.), Gene therapy for neurological disorders and brain tumors. Humana Press, Totowa; 397-408 (1998).

Efficient gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors.

Fraefel C., D.R. Jacoby, C. Lage, H. Hilderbrand, J.Y. Chou, F.W. Alt, X.O. Breakefield and J.A. Majzoub
Mol. Med. 3:813-825 (1997)

Green fluorescent protein as a reporter for retrovirus and helper virus-free HSV-1 amplicon vector-mediated gene transfer into neural cells in culture and in vivo.

Aboody-Guterman KS, Pechan PA, Rainov NG, Sena-Esteves M, Jacobs A, Snyder EY, Wild P, Schraner E, Tobler K, Breakefield XO, Fraefel C. Neuroreport. 1997 Dec 1;8(17):3801-8

HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells.

Johnston KM, Jacoby D, Pechan PA, Fraefel C, Borghesani P, Schuback D, Dunn RJ, Smith FI, Breakefield XO. Hum Gene Ther. 1997 Feb 10;8(3):359-70

Helper virus-free herpes simplex virus-1 plasmid vectors for gene therapy of Parkinson’s Disease and other neurodegenerative disorders.

Geller A.I., L. Yu, Y. Wang and C. Fraefel
Exp. Neurol. 144:98-102 (1997)

HSV-1 derived hybrid vectors for gene therapy in the CNS.

Jacoby D., C. Fraefel and X.O. Breakefield
Gene Therapy 4:1281-1283 (1997). Editorial